$COGT News
Last published 1d ago
- 1d agoCOGTJeffries Global Healthcare Conference in London - COGENT BIOSCIENCES INCEarnings Call TranscriptsAll right. Good afternoon, or I guess soon to be evening here in London, everyone. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today the management team of Cogent Bio.
- 1w agoCOGTGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - COGENT BIOSCIENCES INCEarnings Call TranscriptsGood morning, my name is Michael Schmidt, Senior Biotech Analyst with Guggenheim. And the first presenting company here is Cochin Biosciences. With me I have Andrew Robbins, CEO. Andrew, welcome, thanks for joining us. T
- 1w agoCOGTGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - COGENT BIOSCIENCES INCEarnings Call TranscriptsGood morning, my name is Michael Schmidt, Senior Biotech Analyst with Guggenheim. And the first presenting company here is Cochin Biosciences. With me I have Andrew Robbins, CEO. Andrew, welcome, thanks for joining us. T
- 1w agoCOGTCogent Biosciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoCOGTCogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsGlobeNewswirePreparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027 Cash balance of
- 3w agoCOGTCogent Biosciences to Participate in the Guggenheim Healthcare Innovation ConferenceGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 2mo agoCOGTCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)GlobeNewswireNDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set for June 29, 2027
- 3mo agoCOGTCogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial ResultsGlobeNewswireOn track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30 Completed
- 4mo agoCOGTCogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)GlobeNewswireSubmission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for
- 5mo agoCOGTCogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) CongressGlobeNewswire- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145, on track for IND
- 5mo agoCOGTCogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) CongressGlobeNewswire-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria – -- Bezuclastinib
- 5mo agoCOGTJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORKCOGENT BIOSCIENCES INCEarnings Call TranscriptsAll right. Good morning, everyone. Thank you for those of you in the room and those dialed in on the conference call. My name is Pashto Khurshid. I'm one of the senior biotech analysts here at Jefferies, and we are here
- 5mo agoCOGTCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireBezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65,
- 5mo agoCOGTCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GISTGlobeNewswireNDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30, 2026 Bezuclastinib
- 5mo agoCOGTCogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 6mo agoCOGTCogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 CongressGlobeNewswirePivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent's third oral presentation of pivotal data with bezuclastinib at major medical meetings Preclinical data from
- 6mo agoCOGTCogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial ResultsGlobeNewswire- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation at 2026 ASCO
- 7mo agoCOGTCogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., April 21, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 7mo agoCOGTCogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewswire– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors – Updated presentation on
- 7mo agoCOGTCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)GlobeNewswireBezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination demonstrated
- 8mo agoCOGTCogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)GlobeNewswireWALTHAM, Mass. and BOULDER, Colo., March 16, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 8mo agoCOGTCogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual MeetingGlobeNewswireBezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with
- 9mo agoCOGTCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireSUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib in patients with 2L
- 9mo agoCOGTCogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual MeetingGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 9mo agoCOGTCogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)GlobeNewswire- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 (GLOBE
- 10mo agoCOGTCogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)GlobeNewswire- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in
- 10mo agoCOGTCogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies PortfolioGlobeNewswireNew Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new
- 10mo agoCOGTCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic MastocytosisGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 11mo agoCOGTCogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)GlobeNewswire-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a
- 11mo agoCOGTCogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)GlobeNewswire-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that
- 1y agoCOGTCogent Biosciences Announces Participation in the Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 1y agoCOGTCogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031GlobeNewswireWALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined
- 1y agoCOGTCogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common StockGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined
- 1y agoCOGTCogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)GlobeNewswire16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; p<0.0001) 46% Objective Response Rate (ORR) reported
- 1y agoCOGTCogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial ResultsGlobeNewswirePhase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA)
- 1y agoCOGTCogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) MeetingGlobeNewswireSUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest preclinical program;
- 1y agoCOGTCogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 1y agoCOGTCogent Biosciences Announces FDA Breakthrough Therapy Designation for BezuclastinibGlobeNewswireDetailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this yearNDA submission
- 1y agoCOGTCogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass. and BOULDER, Colo., Sept.
- 1y agoCOGTCogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoCOGTCogent Biosciences Announces Participation in the Citi Biopharma ConferenceGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 1y agoCOGTCogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial ResultsGlobeNewswireReported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints
- 1y agoCOGTCogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 1y agoCOGTCogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic MastocytosisGlobeNewswire-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated
- 1y agoCOGTCogent Biosciences Secures up to $400 Million in Non-Dilutive FinancingGlobeNewswireFacility provides additional funding for next steps of the Company's growth, including the expected launch of bezuclastinib in 2026 On track to report results from three pivotal trials this year, beginning with SUMMIT
- 1y agoCOGTCogent Biosciences Announces Participation in the Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 1y agoCOGTCogent Biosciences Reports First Quarter 2025 Financial ResultsGlobeNewswireThree Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year
- 1y agoCOGTCogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New LeadersGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 1y agoCOGTCogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
- 1y agoCOGTCogent Biosciences Announces Participation in the Leerink Healthcare ConferenceGlobeNewswireWALTHAM, Mass. and BOULDER, Colo., March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today